Carcinoma

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the…

An elderly man presented with a violaceous lesion on his face that gradually increased in size and spread to his…

New York, USA, July 24, 2023 (GLOBE NEWSWIRE) -- Advanced Renal Cell Carcinoma Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 50 Key Companies Working in the…

FORT LEE, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., and a fully integrated biopharmaceutical company dedicated to…

Adjuvant therapy with nivolumab (Opdivo) was feasible and safe and appeared to prolong disease-free survival (DFS)…

MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) --…

The first-line treatment options for advanced and metastatic non-clear cell renal cell…

New York, USA, June 26, 2023 (GLOBE NEWSWIRE) -- Hepatocellular Carcinoma Clinical Trial Analysis: DelveInsight Evaluates a Robust Pipeline as 90+ Influential Pharma Players to Set Foot…

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved…

<!-- Name:DistributionId Value:8827692 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…